Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Kovac, Michal, Blattmann, Claudia, Ribi, Sebastian, Smida, Jan, Mueller, Nikola S., Engert, Florian, Castro-Giner, Francesc, Weischenfeldt, Joachim +19 more·2015·Nature Communications
DOI 10.1038/ncomms9940

Cited by (347)

Items 101–200 of 347

  1. HACE1 is a potential tumor suppressor in osteosarcoma
    Amal M. El-Naggar, Paul W. Clarkson, Gian Luca Negri, Busra Turgu, Fan Zhang, Michael S. Anglesio, Poul H. B. Sorensen · 2019 · Cell Death and Disease
  2. Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors
    Katia Scotlandi, Claudia Maria Hattinger, Evelin Pellegrini, Marco Gambarotti, Massimo Serra · 2020 · Cells
  3. FENDRR: A pivotal, cancer-related, long non-coding RNA
    Qingyuan Zheng, Qiyao Zhang, Xiao Yu, Yuting He, Wenzhi Guo · 2021 · Biomedicine & Pharmacotherapy
  4. Next-generation sequencing for the management of sarcomas with no known driver mutations
    Simon Vyse, Khin Thway, Paul H. Huang, Robin L. Jones · 2021 · Current Opinion in Oncology
  5. Advances in sarcoma gene mutations and therapeutic targets
    Peng Gao, Nicole A. Seebacher, Francis John Hornicek, Zheng Guo, Zhenfeng Duan · 2017 · Cancer Treatment Reviews
  6. The genomics of undifferentiated sarcoma of soft tissue: Progress, challenges and opportunities
    Christopher D. Steele, Nischalan Pillay · 2019 · Seminars in Cancer Biology
  7. Comparison of Tumor- and Bone Marrow-Derived Mesenchymal Stromal/Stem Cells from Patients with High-Grade Osteosarcoma
    Louis‐Romée Le Nail, Meadhbh Á. Brennan, Philippe Rosset, Frédéric Deschaseaux, Philippe Piloquet, Olivier Pichon, Cédric Le Caignec, Vincent Crenn, Pierre Layrolle, Olivier Hérault et al. · 2018 · International Journal of Molecular Sciences
  8. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas
    Hongyi Li, Jian Tu, Zhiqiang Zhao, Lijuan Chen, Yueting Qu, Hongbo Li, Hao Yao, Xiaoshuai Wang, Dung‐Fang Lee, Jingnan Shen et al. · 2020 · Theranostics
  9. Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma
    Michael David Kinnaman, Simone Zaccaria, Alvin P. Makohon-Moore, Brian Arnold, Max Fine Levine, Gunes Gundem, Juan Arango Ossa, Dominik Głodzik, Irene Rodriguez-Sanchez, Nancy Bouvier et al. · 2023 · Cancer Research
  10. Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma
    Peng Yan, Jie Wang, Bin Yue, Xinyi Wang · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  11. Sono-activable and biocatalytic 3D-printed scaffolds for intelligently sequential therapies in osteosarcoma eradication and defect regeneration
    Xiao Rong, Sutong Xiao, Wei Geng, Bihui Zhu, Ping Mou, Zichuan Ding, Boqing Zhang, Yujiang Fan, Li Qiu, Chong Cheng · 2025 · Nature Communications
  12. Pioneer factors in development and cancer
    Benjamin D. Sunkel, Benjamin Z. Stanton · 2021 · iScience
  13. Targeting metastasis in paediatric bone sarcomas
    Emma C. Bull, Archana Singh, Amy M. Harden, Kirsty Soanes, Hala Habash, Lisa Toracchio, Marianna Carrabotta, Christina Schreck, Karan Mehul Shah, Paulina Velasco Riestra et al. · 2025 · Molecular Cancer
  14. Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas (Review)
    Xiaolei Ren, Chao Tu, Zhenchu Tang, Ruofei Ma, Zhihong Li · 2018 · Oncology Letters
  15. Pan-cancer detection of driver genes at the single-patient resolution
    Joel Nulsen, Hrvoje Mišetić, Christopher Yau, Francesca D. Ciccarelli · 2021 · Genome Medicine
  16. Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics
    Michael R. van Gerven, Eva Bozsaky, Yvette A.H. Matser, Julian Vosseberg, Sabine Taschner‐Mandl, Jan Köster, Godelieve A.M. Tytgat, Jan J. Molenaar, Marlinde L. van den Boogaard · 2022 · Cancer Science
  17. The landscape of genetic aberrations in myxofibrosarcoma
    Yasuhide Takeuchi, Kenichi Yoshida, Adriane Halik, Annegret Kunitz, Hiromichi Suzuki, Nobuyuki Kakiuchi, Yusuke Shiozawa, Akira Yokoyama, Yoshikage Inoue, Tomonori Hirano et al. · 2022 · International Journal of Cancer
  18. The Challenges of Detecting Circulating Tumor Cells in Sarcoma
    Marta Tellez-Gabriel, Hannah K. Brown, Robin Young, Marie‐Françoise Heymann, Dominique Heymann · 2016 · Frontiers in Oncology
  19. Prospects for the involvement of cancer stem cells in the pathogenesis of osteosarcoma
    Sama Izadpanah, Parastoo Shabani, Ali Aghebati‐Maleki, Amir Baghbanzadeh, Ali Fotouhi, Amir Bisadi, Leili Aghebati Maleki, Behzad Baradaran · 2019 · Journal of Cellular Physiology
  20. Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies
    Courtney R. Schott, Avanthi Tayi Shah, Alejandro Sweet-Cordero · 2020 · Advances in experimental medicine and biology
  21. Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding
    Suzanne Bartholf DeWitt, Sarah Hoskinson Plumlee, Hailey E. Brighton, Dharshan Sivaraj, E. J. Martz, Maryam Zand, Vardhman Kumar, Maya U. Sheth, Warren Floyd, Jacob Spruance et al. · 2022 · JCI Insight
  22. Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas
    Naofumi Asano, Hideyuki Takeshima, Satoshi Yamashita, Hironori Takamatsu, Naoko Hattori, Takashi Kubo, Akihiko Yoshida, Eisuke Kobayashi, Robert T. Nakayama, Morio Matsumoto et al. · 2019 · Scientific Reports
  23. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma
    Sunetra Das, Rupa Idate, Daniel P. Regan, Jared Scott Fowles, Susan E. Lana, Douglas H. Thamm, Daniel L. Gustafson, Dawn L. Duval · 2021 · Communications Biology
  24. Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs
    David T. Miller, Isidro Cortés‐Ciriano, Nischalan Pillay, Angela C. Hirbe, Matija Snuderl, Marilyn M. Bui, Katherine Piculell, Alyaa Al‐Ibraheemi, Brendan Craig Dickson, Jesse L. Hart et al. · 2020 · Genes
  25. NETWORKCENTRIC HEALTHCARE: OUTLINE OF ENTRY PORTAL CONCEPT
    Dag Von Lubitz, Nilmini S. Wickramasinghe · 2006 · RMIT Research Repository (RMIT University Library)
  26. Clinicopathologic characterization of malignant chondroblastoma: a neoplasm with locally aggressive behavior and metastatic potential that closely mimics chondroblastoma-like osteosarcoma
    David James Papke, Yin Pun Hung, Inga‐Marie Schaefer, Miriam A. Bredella, Gregory W. Charville, John David Reith, Christopher D.�M. Fletcher, G. Petur Nielsen, Jason L. Hornick · 2020 · Modern Pathology
  27. Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma
    Lara Planas‐Paz, Alicia Pliego‐Mendieta, Catherine Hagedorn, Domingo Aguilera‐Garcia, Martina Haberecker, Fabian M. Arnold, Marius Herzog, Lorenz Bankel, Roman Guggenberger, Sabrina Steiner et al. · 2023 · EMBO Molecular Medicine
  28. Re-calculating! Navigating through the osteosarcoma treatment roadblock
    Jeremy McGuire, Thomas J. Utset‐Ward, Damon R. Reed, Conor C. Lynch · 2016 · Pharmacological Research
  29. Fanconi Anaemia, Childhood Cancer and the BRCA Genes
    Emma Roisin Woodward, Stefan Meyer · 2021 · Genes
  30. Challenges and Opportunities for Childhood Cancer Drug Development
    Peter J. Houghton, Raushan T. Kurmasheva · 2019 · Pharmacological Reviews
  31. CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma
    Shintaro Iwata, Yasutoshi Tatsumi, Tsukasa Yonemoto, Akinobu Araki, Makiko Itami, Hiroto Kamoda, Toshinori Tsukanishi, Yoko Hagiwara, Hideyuki Kinoshita, Takeshi Ishii et al. · 2021 · Oncology Reports
  32. Is the osteosarcoma genome targetable?
    Sharon A. Savage, Lisa J. Mirabello · 2017 · Nature Reviews Endocrinology
  33. KLF8 promotes cancer stem cell-like phenotypes in osteosarcoma through miR-429-SOX2 signaling
    L Zhang, Pan‐Chyr Yang, Qin‐Bai Liu, J. Wang, F. YAN, Li Duan, F. LIN · 2020 · Neoplasma
  34. LINC01128 regulates the development of osteosarcoma by sponging miR‐299‐3p to mediate MMP2 expression and activating Wnt/β‐catenin signalling pathway
    Qiang Yao, Ting Chen · 2020 · Journal of Cellular and Molecular Medicine
  35. SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
    Jessica Gartrell, Marcia Mellado-Largarde, Nancy E. Martinez, Michael R. Clay, Armita Bahrami, Natasha Sahr, April Sykes, Kaley Blankenship, Lauren Hoffmann, Jia Xie et al. · 2021 · Molecular Cancer Therapeutics
  36. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment
    Wei Wang, Hua Zhao, Teng-Fei Yao, Hao Gong · 2018 · Investigational New Drugs
  37. Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib
    Christopher L. Heidler, Eva K. Roth, Markus Thiemann, Claudia Blattmann, Ramon Lopez Perez, Peter Ernst Huber, Michal B Kovac, Beate Amthor, Gabriele Neu‐Yilik, Andreas E. Kulozik · 2019 · International Journal of Cancer
  38. Direct conversion of osteosarcoma to adipocytes by targeting TNIK
    Toru Hirozane, Mari Masuda, Teppei Sugano, Tetsuya Sekita, Naoko Goto, Toru Aoyama, Takato Sakagami, Yuko Uno, Hideki Moriyama, Masaaki Sawa et al. · 2021 · JCI Insight
  39. Biomaterials‐Boosted Immunotherapy for Osteosarcoma
    Chao Sun, Shuqiang Li, Jianxun Ding · 2024 · Advanced Healthcare Materials
  40. Osteosarcoma in the Post Genome Era: Preclinical Models and Approaches to Identify Tractable Therapeutic Targets
    Wilson Castillo‐Tandazo, Anthony J. Mutsaers, Carl R. Walkley · 2019 · Current Osteoporosis Reports
  41. Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
    Olaf Beck, Claudia Paret, Alexandra Russo, Jürgen Burhenne, Margaux Fresnais, Kevin Steimel, Larissa Seidmann, Daniel‐Christoph Wagner, Nadine Vewinger, Nadine Lehmann et al. · 2020 · Cancers
  42. Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncology
    Irina A. Kerle, Thomas J Gross, Anja Kögler, Jonas S. Arnold, Maximilian Werner, Jan‐Niklas Eckardt, Elena E. Möhrmann, Marie Arlt, Barbara Hutter, Jennifer Hüllein et al. · 2025 · npj Precision Oncology
  43. Circular RNA Circ-03955 Promotes Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating miR-3662/Metadherin Pathway
    Zhengguang Wang, Mingsi Deng, Liangjian Chen, Weiguo Wang, Gengyan Liu, Dongbiao Liu, Zhipeng Han, Yongfeng Zhou · 2020 · Frontiers in Oncology
  44. miR-486-5p expression is regulated by DNA methylation in osteosarcoma
    Heidi Maria Namløs, Magne Skårn, Deeqa Ahmed, Iwona Grad, Kim Andresen, Stine H. Kresse, Else Munthe, Massimo Serra, Katia Scotlandi, Antonio Llombart‐Bosch et al. · 2022 · BMC Genomics
  45. A novel mutation in ATRX associated with intellectual disability, syndromic features, and osteosarcoma
    Maria Anna Smolle, Ellen Heitzer, Jochen B. Geigl, Ali Al Kaissi, Bernadette Liegl‐Atzwanger, Markus G. Seidel, Lukas A. Holzer, Andreas Leithner · 2017 · Pediatric Blood & Cancer
  46. Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines
    Helin Feng, Heather Sheppard, Gang Wu, Andrew M. Davidoff, Jun Yang · 2018 · Oncotarget
  47. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
    Harriet Holme, Aditi Gulati, Rachel Brough, Emmy D.G. Fleuren, Ilirjana Bajrami, James Campbell, Irene Yu-Shing Chong, Sara Costa-Cabral, Richard J. R. Elliott, Tim R. Fenton et al. · 2018 · Scientific Reports
  48. Recent advances in understanding osteosarcoma and emerging therapies
    Nathalie Gaspar, Maria Eugénia Marques Da Costa, Olivia Fromigué, Robin Droit, Pablo Berlanga, Antonin Marchais · 2020 · Faculty Reviews
  49. First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors
    Masatoshi Takagi, Chitose Ogawa, Tomoko Iehara, Yuki Aoki-Nogami, Eri Ishibashi, Minoru Imai, Toshimi Kimura, Masashi Nagata, Masato Yasuhara, Mitsuko Masutani et al. · 2022 · Cancer
  50. Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas
    Nadège Presneau, Laure Alice Duhamel, Hongtao Ye, Roberto Tirabosco, Adrienne Margaret Flanagan, Malihe Eskandarpour · 2017 · British Journal of Cancer
  51. Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma
    Xiaolan Feng, Erin Pleasance, Eric Y. Stutheit-Zhao, Tony Ng, Jasleen Grewal, Nissreen Mohammad, Sara K. Taylor, Christine E. Simmons, Amirrtha Srikanthan, Shahrad Rod Rassekh et al. · 2019 · JCO Precision Oncology
  52. Gene Prioritization through Consensus Strategy, Enrichment Methodologies Analysis, and Networking for Osteosarcoma Pathogenesis
    Alejandro Cabrera‐Andrade, Andrés López‐Cortés, Gabriela Jaramillo-Koupermann, César Paz‐y‐Miño, Yunierkis Pérez‐Castillo, Cristian Robert Munteanu, Humberto González‐Díaz, Alejandro Pazos, Eduardo Tejera · 2020 · International Journal of Molecular Sciences
  53. The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies
    Michal B Kovac, Baptiste Ameline, Sebastian Ribi, Monika Kováčová, William C. H. Cross, Maxim Barenboim, Olaf Witt, Stefan Bielack, Andreas Heinrich Krieg, Wolfgang Hartmann et al. · 2021 · The Journal of Pathology
  54. Murine models of osteosarcoma: A piece of the translational puzzle
    Mannu Walia, Wilson Castillo‐Tandazo, Anthony J. Mutsaers, Thomas John Martin, Carl R. Walkley · 2017 · Journal of Cellular Biochemistry
  55. Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours
    Winette T.A. van der Graaf, Margot E. T. Tesselaar, Terri Patricia McVeigh, Wim J.G. Oyen, Stefan Fröhling · 2022 · Seminars in Cancer Biology
  56. Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management
    Rose B. McGee, Ninad Oak, Lynn H. Harrison, Ke Xu, Regina Nuccio, Alise K. Blake, Roya M. Mostafavi, Sara Lewis, Leslie M. Taylor, Manish Kubal et al. · 2023 · Clinical Cancer Research
  57. Children's Oncology Group's 2023 blueprint for research: Bone tumors
    Damon R. Reed, Patrick Joseph Grohar, Elyssa M. Rubin, Odion T. Binitie, Mark Krailo, Jessica L. Davis, Steven G. DuBois, Katherine A. Janeway · 2023 · Pediatric Blood & Cancer
  58. Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway
    Karim H. Saba, Valeria Difilippo, Michal B Kovac, Louise Cornmark, Linda Magnusson, Jenny Nilsson, Hilda van den Bos, Diana C.J. Spierings, Mahtab Bidgoli, Tord Jonson et al. · 2023 · The Journal of Pathology
  59. Multiple primary tumors: a case report and review of the literature
    Zhiqing Zhao, Kunkun Sun, Taiqiang Yan, Ran Wei, Wei Guo · 2020 · BMC Musculoskeletal Disorders
  60. Translational cell biology of highly malignant osteosarcoma
    Albert Roessner, Christoph Hubertus Lohmann, Dörthe Jechorek · 2021 · Pathology International
  61. Development of an immune-related prognostic index associated with osteosarcoma
    Chao-Dong Yin, Ying-Lan Hou, Xiao-Ren Liu, Yu-Sheng He, Xinping Wang, Chengjie Li, Xiaohong Tan, Jun Liu · 2020 · Bioengineered
  62. Cellular and Genetic Background of Osteosarcoma
    Inga Urlić, Marijana Šimić Jovičić, Karla Ostojić, Alan Ivković · 2023 · Current Issues in Molecular Biology
  63. Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma
    Laurie Sorenson, Yanfen Fu, Tressa Hood, Sarah E. Warren, Troy A. McEachron · 2019 · OncoImmunology
  64. Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
    Viviana De Martino, Michela Rossi, Giulia Battafarano, Jessica Pepe, Salvatore Minisola, Andrea Del Fattore · 2021 · International Journal of Molecular Sciences
  65. Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma
    Camille Jubelin, Javier Muñoz-García, Denis Cochonneau, Emilie Moranton, Marie‐Françoise Heymann, Dominique Heymann · 2022 · Cancer Drug Resistance
  66. Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement
    Darrell Green, Roelof van Ewijk, Elisa Tirtei, Dimosthenis Andreou, Fredrik Baecklund, Daniel Baumhoer, Stefan Bielack, Rajesh Botchu, Kjetil Boye, Bernadette M. D. Brennan et al. · 2024 · Clinical Cancer Research
  67. Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes
    Roman Tremmel, Daniel Hübschmann, Elke Schaeffeler, Sebastian Pirmann, Stefan Fröhling, Matthias Schwab · 2024 · Pharmacological Reviews
  68. First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
    Yan Zhou, Qingcheng Yang, Yang Dong, Tong Ji, Bing Zhang, Cheng Yang, Shuier Zheng, Lina Tang, Chenliang Zhou, Guowei Qian et al. · 2022 · Clinical Cancer Research
  69. The knockdown of lncRNA DLGAP1‐AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR‐451a/HK2 axis
    Changjun Zheng, Ronghang Li, Shuang Zheng, Hongjuan Fang, Meng Xu, Lei Zhong · 2023 · Cancer Science
  70. Molecular biology of sarcoma
    Michał Fiedorowicz, Ewa Bartnik, Paweł Sobczuk, Paweł Teterycz, Anna Malgorzata Czarnecka · 2019 · Oncology in Clinical Practice
  71. Nano-Encapsulation of Mithramycin in Transfersomes and Polymeric Micelles for the Treatment of Sarcomas
    Óscar Estupiñán, Claudia Rendueles, Paula Suárez, Verónica Rey, Dzohara Murillo, Francisco Morís, Gemma Gutiérrez, María Carmen Blanco‐López, María Matos, René Rodrı́guez · 2021 · Journal of Clinical Medicine
  72. Pharmacogenomics of Second-Line Drugs Used for Treatment of Unresponsive or Relapsed Osteosarcoma Patients
    Claudia Maria Hattinger, Serena Vella, Elisa Tavanti, Marilù Fanelli, Piero Picci, Massimo Serra · 2016 · Pharmacogenomics
  73. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target
    Natasja Franceschini, Raffaele Gaeta, Paul Krimpenfort, Inge H. Briaire‐de Bruijn, Alwine B. Kruisselbrink, Károly Szuhai, Ieva Palubeckaitė, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2021 · Laboratory Investigation
  74. Addressing Doxorubicin Resistance in Bone Sarcomas Using Novel Drug-Resistant Models
    Borja Gallego, Dzohara Murillo, Verónica Rey, Carmen Huergo, Óscar Estupiñán, Aida Rodríguez, Juan Tornín, René Rodrı́guez · 2022 · International Journal of Molecular Sciences
  75. Analysis of the Mutational Landscape of Osteosarcomas Identifies Genes Related to Metastasis and Prognosis and Disrupted Biological Pathways of Immune Response and Bone Development
    Sara Ferreira Pires, Juliana Sobral de Barros, Silvia Souza da Costa, Gabriel Bandeira do Carmo, Marília O. Scliar, André van Helvoort Lengert, Érica Boldrini, Sandra Regini Morini da Silva, Daniel Onofre Vidal, Mariana Camargo Maschietto et al. · 2023 · International Journal of Molecular Sciences
  76. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma
    Verónica Rey, Juan Tornín, Juan José Alba‐Linares, Cristina Robledo, Dzohara Murillo, Aida Rodríguez, Borja Gallego, Carmen Huergo, Cristina Viera, Alejandro Braña et al. · 2024 · EBioMedicine
  77. Copy number analysis identifies tumor suppressive lncRNAs in human osteosarcoma
    Jian‐Jun Xie, De‐Chen Lin, Dhong Hyun Tony Lee, Jennifer Akunowicz, Marc F. Hansen, Carl W. Miller, Masashi Sanada, Motohiro Kato, Tadayuki Akagi, Norihiko Kawamata et al. · 2017 · International Journal of Oncology
  78. Using Liquid Biopsy in the Treatment of Patient with OS
    David Stephen Shulman, Brian D. Crompton · 2020 · Advances in experimental medicine and biology
  79. The Variable Genomic Landscape During Osteosarcoma Progression: Insights From a Longitudinal WGS Analysis
    Debora M. Meijer, Dina Ruano, Inge H. Briaire‐de Bruijn, Pauline M. Wijers‐Koster, Michiel A. J. van de Sande, Hans A. J. Gelderblom, Anne‐Marie Cleton-Jansen, Noel F.C.C. de Miranda, Marieke L. Kuijjer, Judith V.M.G. Bovée · 2024 · Genes Chromosomes and Cancer
  80. Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?
    Claudia Maria Hattinger, Maria Pia Patrizio, Elisa Tavanti, Silvia Luppi, Federica Magagnoli, Piero Picci, Massimo Serra · 2018 · Expert Review of Molecular Diagnostics
  81. Omic approaches to pediatric bone sarcomas
    Elisa Tirtei, Matteo Cereda, Elvira De Luna, Paola Quarello, Sebastian Dorin Asaftei, Franca Fagioli · 2019 · Pediatric Blood & Cancer
  82. Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?
    Baptiste Ameline, Michal B Kovac, Michaela Nathrath, Maxim Barenboim, Olaf Witt, Andreas Heinrich Krieg, Daniel Baumhoer · 2020 · The Journal of Pathology Clinical Research
  83. Unraveling the chaotic genomic landscape of primary and metastatic canine appendicular osteosarcoma with current sequencing technologies and bioinformatic approaches
    Shirley Chu, Zachary L. Skidmore, Jason Kunisaki, Jason Walker, Malachi Griffith, Obi L. Griffith, Jeffrey N. Bryan · 2021 · PLoS ONE
  84. Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis
    Stuart J. Gallagher, Teresa A. Bailey, Robert V. Rawson, Annabelle M. Mahar, John F. Thompson, Georgina Venetia Long, James S. Wilmott, Richard A. Scolyer · 2021 · Pathology
  85. DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma
    Maxim Barenboim, Michal B Kovac, Baptiste Ameline, David Jones, Olaf Witt, Stefan Bielack, Stefan E.G. Burdach, Daniel Baumhoer, Michaela Nathrath · 2021 · PLoS Computational Biology
  86. A Comprehensive Understanding of the Genomic Bone Tumor Landscape: A Multicenter Prospective Study
    Xianbiao Xie, Yiying Bian, Haomiao Li, Junqiang Yin, Lantian Tian, Renbing Jiang, Ziliang Zeng, Xiaoliang Shi, Zixiong Lei, Changhe Hou et al. · 2022 · Frontiers in Oncology
  87. Identification of germline cancer predisposition variants in pediatric sarcoma patients from somatic tumor testing
    Piedad Alba‐Pavón, Lide Alaña, Miriam Gutiérrez-Jimeno, Susana García‐Obregón, Teresa Imízcoz, Elena Panizo, Paula González Urdiales, Aizpea Echebarria-Barona, Ricardo López Almaraz, Laura Zaldumbide et al. · 2023 · Scientific Reports
  88. Integrins identified as potential prognostic markers in osteosarcoma through multi-omics and multi-dataset analysis
    Lei Cui, Shuai Zhao, Haibo Teng, Biao Yang, Qian Liu, An Qin · 2025 · npj Precision Oncology
  89. Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell
    Jir‐You Wang, Chao-Ming Chen, Cheng‐Fong Chen, Po‐Kuei Wu, Wei‐Ming Chen · 2021 · International Journal of Molecular Sciences
  90. Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression
    Natasja Franceschini, Jan Oosting, Maud Tamsma, Bertine Niessen, Inge H. Briaire‐de Bruijn, Brendy van den Akker, Alwine B. Kruisselbrink, Ieva Palubeckaitė, Judith V.M.G. Bovée, Anne‐Marie Cleton-Jansen · 2021 · International Journal of Molecular Sciences
  91. Osteosarcoma
    John M. Gross, Meera Hameed · 2025 · Surgical pathology clinics
  92. CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis
    Irenaeus C.C. Chan, Pu Zhang, Xiangyu Pan, Cynthia Castro, Nina Fox, Alexander M. Lewis, Kenyon Weis, Maria Adriana Cuibus, Steven Tittley, Giulia E.M. Petrone et al. · 2026 · Nature Genetics
  93. Molecular and immunohistochemical testing of bone tumours: review and update
    S Krisztian Kovacs, Atikankul Manassaporn, G. Petur Nielsen, Yin Pun Hung · 2022 · Histopathology
  94. From biology to personalized medicine: Recent knowledge in osteosarcoma
    Audrey Mohr, Maria Eugénia Marques Da Costa, Olivia Fromigué, Baptiste Audinot, Thierno Balde, Robin Droit, Samuel D. Abbou, Pierre Khneisser, Pablo Berlanga, Esperanza Pérez et al. · 2024 · European Journal of Medical Genetics
  95. Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
    Hanna E. Persha, Shumei Kato, Pradip K. De, Jacob J. Adashek, Jason Keith Sicklick, Vivek Subbiah, Razelle Kurzrock · 2022 · Journal of Hematology & Oncology
  96. Invited Review: Dysregulation of chromatin remodellers in paediatric brain tumours – SMARCB1 and beyond
    Pascal David Johann · 2020 · Neuropathology and Applied Neurobiology
  97. SOX9 is a key component of RUNX2-regulated transcriptional circuitry in osteosarcoma
    Young‐Im Kim, Yu‐Chou Tseng, Gamze Ayaz, Shasha Wang, Hualong Yan, Wendy du Bois, Howard Hua Yang, Tao Zhen, Maxwell P. Lee, Paul Liu et al. · 2023 · Cell & Bioscience
  98. Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol
    Masatoshi Takagi, Chitose Ogawa, Yuki Aoki-Nogami, Tomoko Iehara, Eri Ishibashi, Minoru Imai, Tetsuro Kihara, Kiyoshi Nobori, Kazuhisa Hasebe, Shuki Mizutani et al. · 2019 · BMC Pediatrics
  99. Endoplasmic reticulum protein 29 (ERp29) as a novel prognostic marker and tumor suppressor in osteosarcoma
    Parunya Chaiyawat, Dumnoensun Pruksakorn, Prach Pipatwattana, Areerak Phanphaisarn, Pimpisa Teeyakasem, Jeerawan Klangjorhor, Jongkolnee Settakorn · 2019 · Journal of bone oncology
  100. Whole-exome sequencing in osteosarcoma with distinct prognosis reveals disparate genetic heterogeneity
    Weifeng Liu, Renxian Wang, Yanrui Zhang, Huina Wang, Zhen Huang, Tao Jin, Yongkun Yang, Yang Sun, Shanbo Cao, Xiaohui Niu · 2021 · Cancer Genetics